MJ33 (lithium salt)

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    MJ33 is an inhibitor of the acidic, calcium-independent (ai)PLA2 activity of Prdx6.
    Peroxiredoxin-6 (Prdx6), a bifunctional enzyme, has both non-selenium glutathione peroxidase and phospholipase A2 (PLA2) activities. The PLA2 activity of Prdx6 is calcium-independent, functions optimally in acidic conditions, and facilitates the intracellular processing of surfactant lipids, such as dipalmitoylphosphatidylcholine.
    In vitro: MJ33 was found to be specifically inhibit the aiPLA2 activity of the protein. Moreover, the Ca2+-independent PLA2 activity of phosphorylated rat Prdx6 could be abolished by the treatment of either MJ33 or surfactant protein A (SP-A), known inhibitors of aiPLA2 activity. Further supporting the results with intact cells, recombinant Prdx6 was phosphorylated in vitro by ERK and p38, but not by JNK. Phosphorylation in vitro led to a great increase in PLA2 activity that was Ca2+-independent and ould be inhibited by both MJ33 and by SP-A, which was similar to native lung enzyme [1].
    In vivo: A previous study evaluated the effect of MJ33 on manifestations of acute lung injury. Results showed that MJ33 could inhibit reactive oxygen species generation by lungs when measured LPS treatment. LPS at either a low or high dose significantly increased lung infiltration with inflammatory cells, secretion of proinflammatory cytokines, expression of lung vascular cell adhesion molecule, lung permeability, tissue lipid peroxidation, tissue protein oxidation, and activation of NF-κB. MJ33, given either concurrently or 2 h subsequent to LPS, was able to significantly reduce all of these measured parameters [2].
    Clinical trial: So far, no clinical study has been conducted.
    
    [1] Wu, Y. ,Feinstein, S.I.,Manevich, Y., et al. Mitogen-activated protein kinase-mediated phosphorylation of peroxiredoxin 6 regulates its phospholipase A2 activity. Biochem. 419(3), 669-679 (2009).
    [2] Lee I, Dodia C, Chatterjee S, Feinstein SI, Fisher AB. Protection against LPS-induced acute lung injury by a mechanism-based inhibitor of NADPH oxidase (type 2). Am J Physiol Lung Cell Mol Physiol. 2014 Apr 1;306(7):L635-44.
- Properties
  - Alternative Name
    
    mono[1-[(hexadecyloxy)methyl]-2-(2,2,2-trifluoroethoxy)ethyl] monomethyl ester phosphoric acid, monolithium salt
    
    CAS Number
    
    1007476-63-2;199106-13-3
    
    Molecular Formula
    
    C22H43F3O6P·Li
    
    Molecular Weight
    
    498.5
    
    Appearance
    
    A crystalline solid
    
    Purity
    
    Purity ≥ 95.00%
    
    Solubility
    
    ≤2mg/ml in ethanol;0.25mg/ml in DMSO;0.5mg/ml in dimethyl formamide
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Wen-ying Yang, Xiang Meng, et al. "PRDX6 Alleviates Lipopolysaccharide-induced Inflammation in Human Gingival Fibroblasts by Regulation of NRF2." Research Square. rs-1108989/v1.
    2. Lu B, Chen XB, et al. "Identification of PRDX6 as a regulator of ferroptosis." Acta Pharmacol Sin. 2019 Apr 29. PMID:31036877

MJ33 (lithium salt)

Background

We Also Recommend

6-OAU

Calpain Inhibitor XII

ML-291